COMMUNIQUÉS West-GlobeNewswire

Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression

18/01/2019 - 16:00

– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets of patients with pancreatic cancer – – Analysis of a previously conducted, randomized Phase 3 trial reveals patients with lymph [...]

NUSCULPT Opens New Practice in Cincinnati, OH Area

18/01/2019 - 15:39

This location provides patients with advanced body sculpting treatments and other cosmetic services CINCINNATI, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Unveiling the opening of a new practice in Crestview Hills, KY, just [...]

InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmissions at LINC, 22nd to the 25th January 2019, in Leipzig, Germany

18/01/2019 - 15:34

Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented TEL AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention [...]

Coherus BioSciences Announces New Employment Inducement Grants

18/01/2019 - 15:30

REDWOOD CITY, Calif., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective January 17, 2019, the compensation committee of the company’s board of directors granted [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

18/01/2019 - 15:01

FIT Biotech Oy Company release January 18, 2019 at 04:00 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 [...]

Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz

18/01/2019 - 14:45

MINNEAPOLIS, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its chief executive officer and director, Carl Schwartz, has made an [...]

Yield Growth Expands Innovative Topicals Line into Oregon -- CFN Media

18/01/2019 - 14:30

SEATTLE, Jan. 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]

Micron Waste Secures Key Patents As It Looks to Cannabis and Beyond-- CFN Media

18/01/2019 - 14:30

SEATTLE, Jan. 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]

EDAP TMS SA : EDAP Announces the Purchase of Focal One® HIFU by Maimonides Medical Center, Brooklyn, NY

18/01/2019 - 14:01

Maimonides Medical Center to Become the First Hospital on the East Coast of the US to Acquire Focal One Technology and Offer the World's Most Advanced HIFU Prostate Treatment LYON, France - January 18, 2019 - EDAP TMS [...]

Aura Enters PR Campaign in Western Canada & Grants Options to Director

18/01/2019 - 14:00

TORONTO, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Aura Health Inc. (the " Company " or “ Aura ”) ( CSE:BUZZ ) is pleased to announce that the Company has entered into a strategic PR campaign in Western Canada with R. Ian [...]

Media Advisory: Top Smoking Cessation Experts Meet in Ottawa

18/01/2019 - 14:00

OTTAWA, Jan. 18, 2019 (GLOBE NEWSWIRE) -- National and international smoking cessation authorities are gathering in Ottawa today to attend the 11 th Annual Ottawa Conference: State of the Art Clinical Approaches to [...]

Avis aux médias : Les plus grands experts de l’abandon du tabac se rassemblent à Ottawa

18/01/2019 - 14:00

OTTAWA, 18 janv. 2019 (GLOBE NEWSWIRE) -- Des experts du Canada et du monde entier se rassemblent à Ottawa aujourd’hui dans le cadre de la 11 e Conférence annuelle d’Ottawa : Approches cliniques : nouvelles tendances en [...]

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

18/01/2019 - 14:00

Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on January 18, 2019 HOUSTON, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its [...]

CTD Announces Partnership with United BioSource LLC (UBC) to support the Extension Protocol for its Phase I Clinical Trial in the United States

18/01/2019 - 14:00

Collaboration will allow patients in Extension Protocol to receive CTD’s drug intravenously at home ALACHUA, Fla., Jan. 18, 2019 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology [...]

TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer

18/01/2019 - 14:00

68% of evaluable patients with actively progressing end-stage pancreatic cancer receiving monotherapy SM-88 remain alive with a median follow-up of 4.3 months (median 5.8 months from completing last therapy) Of 14 [...]

Aleafia Health Completes Strategic Investment in Australia’s CannaPacific Pty Limited

18/01/2019 - 13:56

Global Expansion Underway with 10% Equity Investment in Licensed Cannabis Cultivator CannaPacific among Australia’s only Federally Licensed Cultivators with projected 108,000 sq. ft. Greenhouse TORONTO, Jan. 18, 2019 ( [...]

KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting

18/01/2019 - 13:30

Posters include intranasal and oral HAP data for serdexmethylphenidate (SDX), as well as PK data for KP415 Intranasal HAP data selected to be presented during oral “data blitz session” CELEBRATION, Fla., Jan. 18, 2019 ( [...]

Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019

18/01/2019 - 13:00

CRANBURY, N.J., Jan. 18, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today [...]

AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis

18/01/2019 - 13:00

Phase 1/2 study to be led by team at University of California, San Diego, with rights licensed to AVROBIO CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”) a Phase 2 [...]